Gilead Sciences Inc

More Details of Gilead Sciences Inc Company

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.

Company Info

Company codeGILD

Company nameGilead Sciences Inc

IPO dateJan 22, 1992

Founded at1987

CEOMr. Daniel P. O'Day

Number of employees17600

Security typeOrdinary Share

Fiscal year-endJan 22

Address333 Lakeside Dr

CityFOSTER CITY

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code94404-1147

Phone16505743000

Websitehttps://www.gilead.com/

Company codeGILD

IPO dateJan 22, 1992

Founded at1987

Company Executives

Name

Name/Position

Position

Shareholding

Change

Ms. Johanna Mercier

Chief Commercial Officer

96.93K

+4.50%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

24.54K

--

Ms. Deborah H. (Deb) Telman

Executive Vice President - Corporate Affairs, General Counsel

19.55K

+12.77%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

10.23K

--

Ms. Kelly A. Kramer

Independent Director

1.34K

--

Mr. Harish Manwani

Independent Director

--

Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.

Independent Director

--

Dr. Dietmar P. Berger, M.D., Ph.D.

Chief Medical Officer

--

Dr. Ted W. Love, M.D.

Independent Director

--

Mr. Andrew D. (Andy) Dickinson

Chief Financial Officer

--

Name

Name/Position

Position

Shareholding

Change

Ms. Johanna Mercier

Chief Commercial Officer

96.93K

+4.50%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

24.54K

--

Ms. Deborah H. (Deb) Telman

Executive Vice President - Corporate Affairs, General Counsel

19.55K

+12.77%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

10.23K

--

Ms. Kelly A. Kramer

Independent Director

1.34K

--

Mr. Harish Manwani

Independent Director

--

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

By BusinessUSD

Name

Revenue

Proportion

Biktarvy

13.42B

46.69%

Descovy

2.11B

7.35%

Genvoya

1.76B

6.13%

Sofosbuvir/Velpatasvir

1.59B

5.55%

Yescarta

1.57B

5.46%

Other

8.29B

28.83%

By RegionUSD

Name

Revenue

Proportion

United States

19.51B

67.84%

Europe

4.35B

15.12%

Other Locations

2.91B

10.11%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Biktarvy

13.42B

46.69%

Descovy

2.11B

7.35%

Genvoya

1.76B

6.13%

Sofosbuvir/Velpatasvir

1.59B

5.55%

Yescarta

1.57B

5.46%

Other

8.29B

28.83%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.22%

BlackRock Institutional Trust Company, N.A.

5.97%

Capital World Investors

5.75%

State Street Global Advisors (US)

4.84%

Capital Research Global Investors

4.65%

Other

69.56%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.22%

BlackRock Institutional Trust Company, N.A.

5.97%

Capital World Investors

5.75%

State Street Global Advisors (US)

4.84%

Capital Research Global Investors

4.65%

Other

69.56%

Type

Shareholder

Proportion

Investment Advisor

42.57%

Investment Advisor/Hedge Fund

35.44%

Research Firm

3.19%

Pension Fund

3.00%

Sovereign Wealth Fund

1.73%

Bank and Trust

1.70%

Hedge Fund

1.59%

Insurance Company

0.15%

Foundation

0.13%

Other

10.49%

Institutional Shareholding

Update time: Sun, Jan 19

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

3240

1.12B

90.10%

+6.51M

2024Q4

3313

1.12B

90.13%

+4.63M

2024Q3

3207

1.10B

88.48%

-11.56M

2024Q2

3188

1.10B

88.24%

-14.37M

2024Q1

3196

1.10B

88.13%

-22.04M

2023Q4

3252

1.11B

88.75%

-8.79M

2023Q3

3190

1.10B

88.14%

-23.58M

2023Q2

3196

1.10B

88.02%

-11.22M

2023Q1

3195

1.09B

87.26%

-11.17M

2022Q4

3203

1.08B

86.64%

+1.09M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

114.97M

9.22%

+203.25K

+0.18%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

74.47M

5.97%

-1.75M

-2.30%

Dec 31, 2024

Capital World Investors

71.71M

5.75%

-4.84M

-6.33%

Dec 31, 2024

State Street Global Advisors (US)

60.38M

4.84%

+210.06K

+0.35%

Dec 31, 2024

Capital Research Global Investors

57.95M

4.65%

-3.85M

-6.24%

Dec 31, 2024

Wellington Management Company, LLP

35.66M

2.86%

+1.06M

+3.06%

Dec 31, 2024

Fidelity Management & Research Company LLC

34.64M

2.78%

+6.42M

+22.73%

Dec 31, 2024

Dodge & Cox

32.95M

2.64%

-98.02K

-0.30%

Dec 31, 2024

Geode Capital Management, L.L.C.

28.29M

2.27%

+749.05K

+2.72%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

25.78M

2.07%

+346.10K

+1.36%

Feb 28, 2025

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

VanEck Biotech ETF

12%

Invesco Nasdaq Biotechnology ETF

10.22%

ProShares Ultra Nasdaq Biotechnology

7.84%

iShares Biotechnology ETF

7.01%

Invesco Biotechnology & Genome ETF

6.3%

First Trust NASDAQ Pharmaceuticals ETF

6.11%

VanEck Morningstar Wide Moat Value ETF

5.8%

Global X US Cash Flow Kings 100 ETF

5.67%

Simplify Health Care ETF

4.99%

USCF Dividend Income Fund

4.95%

VanEck Biotech ETF

Proportion12%

Invesco Nasdaq Biotechnology ETF

Proportion10.22%

ProShares Ultra Nasdaq Biotechnology

Proportion7.84%

iShares Biotechnology ETF

Proportion7.01%

Invesco Biotechnology & Genome ETF

Proportion6.3%

First Trust NASDAQ Pharmaceuticals ETF

Proportion6.11%

VanEck Morningstar Wide Moat Value ETF

Proportion5.8%

Global X US Cash Flow Kings 100 ETF

Proportion5.67%

Simplify Health Care ETF

Proportion4.99%

USCF Dividend Income Fund

Proportion4.95%

Dividend

A total of 18.49B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Feb 11, 2025

GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025

Mar 14, 2025

Mar 28, 2025

Mar 14, 2025

Nov 12, 2024

GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024

Dec 13, 2024

Dec 30, 2024

Dec 13, 2024

Aug 13, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024

Sep 13, 2024

Sep 27, 2024

Sep 13, 2024

Apr 26, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024

Jun 14, 2024

Jun 27, 2024

Jun 14, 2024

Feb 06, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Mar 28, 2024

Mar 14, 2024

Nov 08, 2023

GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023

Dec 15, 2023

Dec 28, 2023

Dec 14, 2023

Aug 07, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Sep 28, 2023

Sep 14, 2023

Apr 28, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Jun 29, 2023 going ex on Jun 14, 2023

Jun 15, 2023

Jun 29, 2023

Jun 14, 2023

Feb 02, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Mar 30, 2023 going ex on Mar 14, 2023

Mar 15, 2023

Mar 30, 2023

Mar 14, 2023

Oct 27, 2022

GILD.NB Final Cash Dividend of gross USD 0.73 paid on Dec 29, 2022 going ex on Dec 14, 2022

Dec 15, 2022

Dec 29, 2022

Dec 14, 2022

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

103.190USD

Gilead Sciences Inc

103.190

Overview

Company